Summit Therapeutics (SMMT) is down -12.5%, or -$3.54 to $24.71.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics price target raised to $33 from $30 at Clear Street
- Ivonescimab’s Promising Potential to Outperform KEYTRUDA: A Strong Buy Recommendation
- Summit Therapeutics Reports Q2 2025 Progress and Financials
- Closing Bell Movers: Green Dot up 20% after Q2 beat and raise
- Summit Therapeutics Amends Stock Distribution Agreement